Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures
2022-500302-18-00Phase 2Completed
- Sponsor
- Equilibre Biopharmaceuticals
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in epilepsy comparing EQU-001 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Median percentage change in overall number of countable observable seizures per 28-day period during double-blind treatment vs baseline. Started Feb 2023; status: completed.
02
Drugs
equ-001
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2022-500302-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500302-18-00.